Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2017 | Pages:
103 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H1 2017 Summary Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) pipeline Target constitutes close to 24 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Fibroblast Growth Factor Receptor 4 - Pipeline Review, H1 2017, outlays comprehensive information on the Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Fibroblast growth factor receptor 4 is a protein encoded by the FGFR4 gene. It plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. It is required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. It phosphorylates PLCG1 and FRS2. Ligand binding leads to the activation of several signaling cascades. The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 10, 5, 5 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Metabolic Disorders, Gastrointestinal, Central Nervous System and Musculoskeletal Disorders which include indications Hepatocellular Carcinoma, Solid Tumor, Bile Duct Cancer (Cholangiocarcinoma), Type 2 Diabetes, Breast Cancer, Esophageal Cancer, Gastric Cancer, Lung Adenocarcinoma, Lymphoma, Melanoma, Non-Alcoholic Steatohepatitis (NASH), Non-Small Cell Lung Cancer, Obesity, Ovarian Cancer, Recurrent Glioblastoma Multiforme (GBM), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Chronic Lymphocytic Leukemia (CLL), Constipation, Endometrial Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Fibrosis, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Metastatic Biliary Tract Cancer, Metastatic Melanoma, Metastatic Transitional (Urothelial) Tract Cancer, Nasopharyngeal Cancer, Non-Small Cell Lung Carcinoma, Osteosarcoma, Peritoneal Cancer, Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis, Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Small-Cell Lung Cancer, Spinal Cord Injury, Thymic Carcinoma, Thyroid Cancer and Transitional Cell Cancer (Urothelial Cell Cancer). Furthermore, this report also reviewsalso reviews key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - The report reviews Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects - The report assesses Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Overview Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Companies Involved in Therapeutics Development Amgen Inc ArQule Inc Astellas Pharma Inc AstraZeneca Plc Blueprint Medicines Corp Bristol-Myers Squibb Company Eisai Co Ltd Eli Lilly and Company Genosco Inc H3 Biomedicine Inc Incyte Corp Ionis Pharmaceuticals Inc Johnson & Johnson NGM Biopharmaceuticals Inc Novartis AG Principia Biopharma Inc Tasly Pharmaceutical Group Co Ltd Vichem Chemie Research Ltd Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Drug Profiles ARQ-087 - Drug Profile Product Description Mechanism Of Action R&D Progress ASP-5878 - Drug Profile Product Description Mechanism Of Action R&D Progress AZ-709 - Drug Profile Product Description Mechanism Of Action R&D Progress BLU-554 - Drug Profile Product Description Mechanism Of Action R&D Progress BLU-9931 - Drug Profile Product Description Mechanism Of Action R&D Progress BMS-986036 - Drug Profile Product Description Mechanism Of Action R&D Progress erdafitinib - Drug Profile Product Description Mechanism Of Action R&D Progress ES-135 - Drug Profile Product Description Mechanism Of Action R&D Progress FGF-401 - Drug Profile Product Description Mechanism Of Action R&D Progress golvatinib tartrate + lenvatinib mesylate - Drug Profile Product Description Mechanism Of Action R&D Progress H-3B6527 - Drug Profile Product Description Mechanism Of Action R&D Progress INCB-62079 - Drug Profile Product Description Mechanism Of Action R&D Progress infigratinib - Drug Profile Product Description Mechanism Of Action R&D Progress IONIS-463588 - Drug Profile Product Description Mechanism Of Action R&D Progress lenvatinib mesylate - Drug Profile Product Description Mechanism Of Action R&D Progress LY-2874455 - Drug Profile Product Description Mechanism Of Action R&D Progress NGM-282 - Drug Profile Product Description Mechanism Of Action R&D Progress PRN-1371 - Drug Profile Product Description Mechanism Of Action R&D Progress Recombinant Protein 1 to Agonize Fibroblast Growth Factor Receptor for Fibrosis - Drug Profile Product Description Mechanism Of Action R&D Progress Recombinant Protein to Agonize FGFR for Type 2 Diabetes - Drug Profile Product Description Mechanism Of Action R&D Progress Recombinant Proteins to Agonize FGFR for Metabolic Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Antagonize FGFR4 for Hepatocellular Carcinoma - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit Pan FGFR for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress TSLB-1344 - Drug Profile Product Description Mechanism Of Action R&D Progress Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Dormant Products Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Discontinued Products Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Product Development Milestones Featured News & Press Releases Jun 05, 2017: Eisai to Present Results of Phase Ib/II Study of Anticancer Agent Lenvima (Lenvatinib) in Combination With Anti-PD-1 Antibody Pembrolizumab for the Treatment of Endometrial Carcinoma at 53rd ASCO Annual Meeting Jun 05, 2017: Eisai to Present Results of Phase III Trial of Lenvima (Lenvatinib) as First-line Treatment for Unresectable Hepatocellular Carcinoma in Oral Session at 53rd Asco Annual Meeting May 18, 2017: Eisai to Present Abstracts on Lenvatinib At 53rd ASCO Annual Meeting May 17, 2017: ArQule to Present Clinical Data on ARQ-087 at the 2017 American Society of Clinical Oncology Annual Meeting Apr 22, 2017: Bristol-Myers Squibb's BMS-986036 (Pegylated FGF21) Shows Consistent Improvement in Liver Fat, Liver Injury and Fibrosis in Patients with Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial Apr 22, 2017: NGM Bio Announces NGM282 Dramatically Reduced Liver Fat and Other Biomarkers Associated with Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial Apr 05, 2017: Eisai Presents Data Of Mechanisms Of Action Relating To Tumor Immune Response Regarding Combination Of Anticancer Agent Lenvatinib With Anti-PD-1 Antibody At AACR 108th Annual Meeting Apr 05, 2017: NGM Bio to Present Phase 2 Data of NGM282 in NASH at International Liver Congress 2017 Mar 28, 2017: Eisai to Present Data on Lenvima at 2017 AACR Annual Meeting Mar 28, 2017: German Federal Joint Committee (G-BA) Confirms Additional Benefit of Kisplyx (lenvatinib) in Treatment of Advanced Renal Cell Carcinoma Mar 27, 2017: Blueprint Medicines to Present on BLU-554 at Upcoming Scientific Conferences Mar 23, 2017: Mass. General team identifies mechanisms behind resistance to FGFR inhibitor drug Mar 09, 2017: H3 Biomedicine to Present on H3B-6527 at 2017 American Association of Cancer Research Annual Meeting Jan 25, 2017: Phase III Trial Of Anticancer Agent Lenvima As First-Line Treatment For Unresectable Hepatocellular Carcinoma Meets Primary Endpoint Jan 04, 2017: German Institute for Quality and Efficiency in Health Care Confirms Additional Benefit for Kisplyx (lenvatinib) in Combination with everolimus for the Treatment of Advanced Renal Cell Carcinoma Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H1 2017 Number of Products under Development by Therapy Areas, H1 2017 Number of Products under Development by Indications, H1 2017 Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Indications, H1 2017 (Contd..2), H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Products under Development by Companies, H1 2017 (Contd..4), H1 2017 Number of Products under Investigation by Universities/Institutes, H1 2017 Products under Investigation by Universities/Institutes, H1 2017 Number of Products by Stage and Mechanism of Actions, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Pipeline by Amgen Inc, H1 2017 Pipeline by ArQule Inc, H1 2017 Pipeline by Astellas Pharma Inc, H1 2017 Pipeline by AstraZeneca Plc, H1 2017 Pipeline by Blueprint Medicines Corp, H1 2017 Pipeline by Bristol-Myers Squibb Company, H1 2017 Pipeline by Eisai Co Ltd, H1 2017 Pipeline by Eli Lilly and Company, H1 2017 Pipeline by Genosco Inc, H1 2017 Pipeline by H3 Biomedicine Inc, H1 2017 Pipeline by Incyte Corp, H1 2017 Pipeline by Ionis Pharmaceuticals Inc, H1 2017 Pipeline by Johnson & Johnson, H1 2017 Pipeline by NGM Biopharmaceuticals Inc, H1 2017 Pipeline by Novartis AG, H1 2017 Pipeline by Principia Biopharma Inc, H1 2017 Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2017 Pipeline by Vichem Chemie Research Ltd, H1 2017 Dormant Projects, H1 2017 Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
